Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RDX-002 for Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists for Obesity
NCT06640972Phase 2Completed
- Sponsor
- Response Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RDX-002 in hypertriglyceridemia, obesity, sponsored by Response Pharmaceuticals. Started Sep 2024; status: completed.
02
Drugs
RDX-002
03
Conditions
hypertriglyceridemiaobesity
Beyond the preview
Go deeper on NCT06640972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06640972.